No abstract

No abstract

No abstract

No abstract

Aim: This study calculated the eff ects on serum phosphorus (P) levels, after treatment with either of 2 drugs: the erythropoietin (Epo) and the antioxidant lazaroid (L) drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the certain infl uence, after the respective drug usage in an induced ischemia reperfusion (IR) animal experiment. Materials and methods:The 2 main experimental endpoints at which the serum P levels were evaluated was the 60 th reperfusion min (for the groups A, C and E) and the 120 th reperfusion min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, the groups C and D after Epo administration; whereas the groups E and F after the L administration. Results:The fi rst preliminary study of Epo presented a non signifi cant hyperphosphoremic eff ect by 2.46% + 2.02% (pvalue = 0.2168). However, the second preliminary study of U-74389G presented a non signifi cant hypophosphoremic eff ect by 1.09% + 2.01% (pvalue = 0.5771). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that L is at least 0.4455128-fold [0.4445589 -0.4464687] more hypophosphoremic than Epo (pvalue = 0.0000). Conclusion:The anti-oxidant capacities of U-74389G ascribe at least 0.4455128-fold [0.4445589 -0.4464687] more eff ects than Epo (pvalue = 0.0000).The alterations effects in phosphorus of erythropoietin and U-74389G https://www.heighpubs.org/hbmr https://doi.